Weekly round-up: Infinitopes to Showcase Breakthroughs on Cancer Vaccine Development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial

Infinitopes, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, on Friday announced that it will be presenting three posters on its pioneering cancer vaccine discovery and development, including one that has been recognised as a ‘top 100’ poster presentation, at the Society […]

Why ‘healthspan’ is a vital new concept in life science investing

At the Optimum Strategic Communications’ 16th Annual Healthcare Investor Conference, held on Thursday 10th October 2024 at The King’s Fund, London, Dr Mehmood Khan, CEO of the Hevolution Foundation, spoke to Clive Cookson, Senior Science Writer at the Financial Times, about investing in “healthspan”. What is “healthspan”? Unlike “lifespan” it isn’t an everyday term. Yet […]

Weekly round-up: Strong media coverage for radiopharmaceutical company Ariceum Therapeutics after early success in NHS brain tumour trial

Remarkable results from the start of a trial testing Ariceum Therapeutics’ experimental radiopharmaceutical drug ATT001 in patients with recurrent glioblastoma brain cancer generated strong coverage in the UK’s national media this week. Meanwhile Ariceum’s Chief Operating Officer Greg Mullen featured in an Optimum TV episode, where he explained the highly targeted radiopharmaceutical approach, called Auger […]

This week’s hot topic: Birth rates are collapsing – can IVF help?

By Stephen Adams  Birth rates are collapsing.  This week, it was the turn of England and Wales’s Office for National Statistics (ONS) to report that the fertility rate has dropped to just 1.44 children per woman – the lowest rate since records began in 1938 (1). The replacement rate is 2.08.  This isn’t unique. Birth […]

Sector updates in October

Investment firms  Forbion raised €2B across two funds: Forbion Growth Opportunities III, which is focused on later-stage biotech companies in N America and Europe and Forbion Ventures VII which invests in early therapeutic startups, including new companies the firm creates.  Kurma Partners secures €140M, of €250M goal for its Biofund IV dedicated to investing in […]